Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications

Martina Musella, Gwenola Manic, Ruggero De Maria Marchiano, Ilio Vitale, Antonella Sistigu

Risultato della ricerca: Contributo in rivistaArticolo in rivista

36 Citazioni (Scopus)


If there is a great new hope in the treatment of cancer, the immune system is it. Innate and adaptive immunity either promote or attenuate tumorigenesis and so can have opposing effects on the therapeutic outcome. Originally described as potent antivirals, Type-I interferons (IFNs) were quickly recognized as central coordinators of tumor-immune system interactions. Type-I-IFNs are produced by, and act on, both tumor and immune cells being either host-protecting or tumor-promoting. Here, we discuss Type-I-IFNs in infectious and cancer diseases highlighting their dichotomous role and raising the importance to deeply understand the underlying mechanisms so to reshape the way we can exploit Type-I-IFNs therapeutically.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
Stato di pubblicazionePubblicato - 2017


  • Anticancer therapy
  • IFNs
  • Immunology
  • Immunology and Allergy
  • Oncology
  • cancer stem cells
  • immunotherapy
  • tumor immunity


Entra nei temi di ricerca di 'Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications'. Insieme formano una fingerprint unica.

Cita questo